Jefferies Group restated their buy rating on shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in a research note issued to investors on Wednesday. The firm currently has a $104.00 price target on the pharmaceutical company’s stock.

A number of other research analysts also recently issued reports on the stock. Piper Jaffray Cos. restated a buy rating on shares of Vertex Pharmaceuticals in a research report on Saturday, June 18th. Leerink Swann set a $112.00 price target on shares of Vertex Pharmaceuticals and gave the stock a buy rating in a research report on Saturday, September 17th. RBC Capital Markets restated a buy rating on shares of Vertex Pharmaceuticals in a research report on Saturday, October 1st. Zacks Investment Research downgraded shares of Vertex Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, July 21st. Finally, TheStreet upgraded shares of Vertex Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, July 27th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $117.60.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded up 0.31% on Wednesday, reaching $80.40. 246,216 shares of the company’s stock traded hands. The company has a 50 day moving average price of $91.26 and a 200 day moving average price of $89.81. The firm’s market capitalization is $19.92 billion. Vertex Pharmaceuticals has a 52 week low of $75.90 and a 52 week high of $134.71.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Wednesday, July 27th. The pharmaceutical company reported $0.24 EPS for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.03. Vertex Pharmaceuticals had a negative net margin of 17.77% and a negative return on equity of 12.34%. The firm had revenue of $431.61 million for the quarter, compared to the consensus estimate of $428.08 million. During the same period in the prior year, the firm posted ($0.54) EPS. The firm’s revenue was up 159.9% compared to the same quarter last year. On average, equities research analysts predict that Vertex Pharmaceuticals will post $0.89 earnings per share for the current fiscal year.

In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 6,500 shares of the stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $95.93, for a total transaction of $623,545.00. Following the transaction, the director now owns 274,725 shares in the company, valued at approximately $26,354,369.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Joshua S. Boger sold 47,000 shares of the stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $100.66, for a total value of $4,731,020.00. Following the transaction, the director now owns 274,725 shares in the company, valued at approximately $27,653,818.50. The disclosure for this sale can be found here. Company insiders own 1.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Samlyn Capital LLC boosted its position in Vertex Pharmaceuticals by 19.7% in the first quarter. Samlyn Capital LLC now owns 381,000 shares of the pharmaceutical company’s stock valued at $30,286,000 after buying an additional 62,587 shares during the last quarter. Strs Ohio boosted its position in Vertex Pharmaceuticals by 9.9% in the second quarter. Strs Ohio now owns 346,339 shares of the pharmaceutical company’s stock valued at $29,792,000 after buying an additional 31,241 shares during the last quarter. Bank of Montreal Can purchased a new position in Vertex Pharmaceuticals during the second quarter valued at $14,876,000. Nisa Investment Advisors LLC boosted its position in Vertex Pharmaceuticals by 21.9% in the second quarter. Nisa Investment Advisors LLC now owns 63,375 shares of the pharmaceutical company’s stock valued at $5,452,000 after buying an additional 11,375 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new position in Vertex Pharmaceuticals during the first quarter valued at $1,153,000. Hedge funds and other institutional investors own 96.19% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Stock Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.